MorphoSys AG Share Price Deutsche Boerse AG
Equities
MOR2
US6177602025
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.2 EUR | 0.00% | -1.82% | +92.86% |
Sales 2024 * | 12Cr 13Cr 1.11TCr | Sales 2025 * | 33Cr 35Cr 2.96TCr | Capitalization | 254.43Cr 277.11Cr 23TCr |
---|---|---|---|---|---|
Net income 2024 * | -43Cr -47Cr -3.91TCr | Net income 2025 * | -12Cr -13Cr -1.05TCr | EV / Sales 2024 * | 21.5 x |
Net Debt 2024 * | 8.93Cr 9.72Cr 811.69Cr | Net cash position 2025 * | 9.47Cr 10Cr 860.92Cr | EV / Sales 2025 * | 7.53 x |
P/E ratio 2024 * |
-5.99
x | P/E ratio 2025 * |
-32.5
x | Employees | 464 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 17.23% |
Latest transcript on MorphoSys AG
1 week | -1.82% | ||
Current month | -1.82% | ||
3 months | +1.25% | ||
6 months | +143.61% | ||
Current year | +92.86% |
Managers | Title | Age | Since |
---|---|---|---|
Jean-Paul Kress
CEO | Chief Executive Officer | 59 | 01/19/01 |
Lucinda Crabtree
DFI | Director of Finance/CFO | 45 | 07/23/07 |
Luisa Ciccarelli
CTO | Chief Tech/Sci/R&D Officer | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Brosnan
BRD | Director/Board Member | 69 | 17/18/17 |
Director/Board Member | 67 | 17/18/17 | |
Marc Cluzel
CHM | Chairman | 69 | 31/12/31 |
Date | Price | Change | Volume |
---|---|---|---|
06/24/06 | 16.2 | 0.00% | 0 |
05/24/05 | 16.2 | -4.71% | 0 |
04/24/04 | 17 | +3.03% | 0 |
03/24/03 | 16.5 | 0.00% | 30 |
31/24/31 | 16.5 | 0.00% | 0 |
Delayed Quote Deutsche Boerse AG, June 06, 2024 at 11:47 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.55% | 5.93TCr | |
+43.17% | 4.09TCr | |
-4.71% | 4.02TCr | |
-5.56% | 2.87TCr | |
+13.76% | 2.66TCr | |
-22.00% | 1.89TCr | |
+31.50% | 1.25TCr | |
+2.16% | 1.24TCr | |
+25.70% | 1.23TCr |
- Stock Market
- Equities
- MOR Stock
- MOR2 Stock